drug
HNSCC
Phase 1updated 6mo agoby Metaclipse Therapeutics Corp
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying HNSCC
News(10)
- FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaThe U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and n…fda_press · 12d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 20d ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 20d ago
- Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3Capping off a busy few days in Spain, Genmab reported results from the first interim analysis of a phase 3 trial showing that adding its bispecific antibody petosemtamab to Merck & Co.'s Keytruda c…fiercebiotech · 20d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 28d ago
- BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survivalWhile BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analyst…biospace · 1mo ago
- BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidenceA phase 2/3 clinical trial of BioNTech’s mRNA cancer immunotherapy BNT113 has missed one of its dual primary endpoints. But with immature overall survival data offering a path to redemption, the Ge…fiercebiotech · 1mo ago
- Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerInhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.biospace · 2mo ago
- Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityInhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and nec…fiercebiotech · 2mo ago
- INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCCFirst-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.onclive · 6mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that